Helping The others Realize The Advantages Of HOIPIN-1
MI-CP151 was a stage 1b randomised, double-blind, placebo managed, dose-escalation, multicentre examine to evaluate many intravenous doses of sifalimumab, in adult sufferers with dermatomyositis or polymyositis (NCT00533091). Key trial goals were being To guage the security and tolerability of sifalimumab in dermatomyositis or polymyositis individu